비교리스트

 카트 문의
시장보고서
상품코드
1530949

세계의 인터류킨 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2034년)

Interleukins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 147 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인터류킨 시장 - 조사 범위

TMR 조사 보고서 '인터류킨 세계 시장'은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 본 보고서는 2024년을 기준년, 2034년을 예측년으로, 2018년부터 2034년까지 세계의 인터류킨 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 인터류킨 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서 분석가는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 인터류킨 시장을 추찰했습니다.

시장 현황
2023년 시장 규모 429억 달러
2034년 시장 규모 2,186억 달러
CAGR 15.9%

이 보고서는 세계 인터류킨 시장 경쟁 구도를 파악하고 있습니다. 세계의 인터류킨 시장에서 사업을 전개하는 주요 기업이 확인되고 각 기업은 다양한 속성으로 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT 등이 본 보고서에서 소개되고 있는 세계의 인터류킨 시장에서의 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약: 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

  • 파이프라인 분석
  • 주요 제품·브랜드 분석
  • 주요 M&A
  • COVID-19에 의한 산업에 대한 영향

제6장 세계 시장 분석과 예측 : 유형별

  • 소개 및 정의
  • 주요 조사 결과· 발전
  • 시장 매출 예측 : 유형별, 2020-2034년
    • IL-1
    • IL-5
    • IL-6
    • IL-23
    • 기타(IL-23 등)
  • 시장의 매력 분석 : 유형별

제7장 세계 시장 분석과 예측 : 적응 질환별

  • 소개 및 정의
  • 주요 조사 결과· 발전
  • 시장 매출 예측 : 적응 질환별, 2020-2034년
    • 건선
    • 건선성 관절염
    • 염증성 장질환
    • 강직성 척추염
    • 습진
    • 통풍
    • 기타(피부경화증 등)
  • 시장의 매력 분석 : 적응 질환별

제8장 세계 시장 분석과 예측 : 유통 채널별

  • 소개 및 정의
  • 주요 조사 결과· 발전
  • 시장 매출 예측 : 유통 채널별, 2020-2034년
    • 병원 약국
    • 온라인 약국
    • 소매 약국
  • 시장의 매력 분석 : 유통 채널별

제9장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 매출 예측 :지역별, 2020-2034년
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력 분석 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 구도

  • 시장 기업 - 경쟁 매트릭스(기업 Tier과 규모별)
  • 시장 점유율 분석 : 기업별(2023년)
  • 기업 프로파일
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Regeneron Pharmaceuticals, Inc.
    • Johnson & Johnson
    • AstraZeneca plc
    • Bausch Health
    • GSK plc
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
JHS 24.09.04

Interleukins Market - Scope of Report

TMR's report on the global interleukins market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global interleukins market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global interleukins market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the interleukins market.

Market Snapshot
Market Value in 2023US$ 42.9 Bn
Market Value in 2034US$ 218.6 Bn
CAGR15.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global interleukins market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global interleukins market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global interleukins market.

The report delves into the competitive landscape of the global interleukins market. Key players operating in the global interleukins market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global interleukins market profiled in this report.

Key Questions Answered in Global interleukins Market Report:

  • What is the sales/revenue generated by interleukins across all regions during the forecast period?
  • What are the opportunities in the global interleukins market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Interleukins Market - Research Objectives and Research Approach

The comprehensive report on the global interleukins market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global interleukins market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global interleukins market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Interleukins Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Interleukins Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Interleukins Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2020-2034
    • 6.3.1. IL-1
    • 6.3.2. IL-5
    • 6.3.3. IL-6
    • 6.3.4. IL-23
    • 6.3.5. Others (IL-23, etc.)
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Interleukins Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2020-2034
    • 7.3.1. Psoriasis
    • 7.3.2. Psoriatic Arthritis
    • 7.3.3. Inflammatory Bowel Disease
    • 7.3.4. Ankylosing Spondylitis
    • 7.3.5. Eczema
    • 7.3.6. Gout
    • 7.3.7. Others (Systematic Sclerosis, etc.)
  • 7.4. Market Attractiveness Analysis, by Disease Indication

8. Global Interleukins Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online Pharmacies
    • 8.3.3. Retail Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Interleukins Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Interleukins Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2020-2034
    • 10.3.1. IL-1
    • 10.3.2. IL-5
    • 10.3.3. IL-6
    • 10.3.4. IL-23
    • 10.3.5. Others (IL-23, etc.)
  • 10.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 10.4.1. Psoriasis
    • 10.4.2. Psoriatic Arthritis
    • 10.4.3. Inflammatory Bowel Disease
    • 10.4.4. Ankylosing Spondylitis
    • 10.4.5. Eczema
    • 10.4.6. Gout
    • 10.4.7. Others (Systematic Sclerosis, etc.)
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Online Pharmacies
    • 10.5.3. Retail Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Disease Indication
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Interleukins Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2020-2034
    • 11.3.1. IL-1
    • 11.3.2. IL-5
    • 11.3.3. IL-6
    • 11.3.4. IL-23
    • 11.3.5. Others (IL-23, etc.)
  • 11.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 11.4.1. Psoriasis
    • 11.4.2. Psoriatic Arthritis
    • 11.4.3. Inflammatory Bowel Disease
    • 11.4.4. Ankylosing Spondylitis
    • 11.4.5. Eczema
    • 11.4.6. Gout
    • 11.4.7. Others (Systematic Sclerosis, etc.)
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Online Pharmacies
    • 11.5.3. Retail Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Disease Indication
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Interleukins Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type, 2020-2034
    • 12.3.1. IL-1
    • 12.3.2. IL-5
    • 12.3.3. IL-6
    • 12.3.4. IL-23
    • 12.3.5. Others (IL-23, etc.)
  • 12.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 12.4.1. Psoriasis
    • 12.4.2. Psoriatic Arthritis
    • 12.4.3. Inflammatory Bowel Disease
    • 12.4.4. Ankylosing Spondylitis
    • 12.4.5. Eczema
    • 12.4.6. Gout
    • 12.4.7. Others (Systematic Sclerosis, etc.)
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Online Pharmacies
    • 12.5.3. Retail Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Disease Indication
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Interleukins Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2020-2034
    • 13.3.1. IL-1
    • 13.3.2. IL-5
    • 13.3.3. IL-6
    • 13.3.4. IL-23
    • 13.3.5. Others (IL-23, etc.)
  • 13.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 13.4.1. Psoriasis
    • 13.4.2. Psoriatic Arthritis
    • 13.4.3. Inflammatory Bowel Disease
    • 13.4.4. Ankylosing Spondylitis
    • 13.4.5. Eczema
    • 13.4.6. Gout
    • 13.4.7. Others (Systematic Sclerosis, etc.)
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Online Pharmacies
    • 13.5.3. Retail Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Disease Indication
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Interleukins Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Type, 2020-2034
    • 14.3.1. IL-1
    • 14.3.2. IL-5
    • 14.3.3. IL-6
    • 14.3.4. IL-23
    • 14.3.5. Others (IL-23, etc.)
  • 14.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 14.4.1. Psoriasis
    • 14.4.2. Psoriatic Arthritis
    • 14.4.3. Inflammatory Bowel Disease
    • 14.4.4. Ankylosing Spondylitis
    • 14.4.5. Eczema
    • 14.4.6. Gout
    • 14.4.7. Others (Systematic Sclerosis, etc.)
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Online Pharmacies
    • 14.5.3. Retail Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Disease Indication
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AbbVie Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. F. Hoffmann-La Roche AG
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Regeneron Pharmaceuticals, Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Johnson & Johnson
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. AstraZeneca plc
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bausch Health
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. GSK plc
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Sanofi S.A.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Sun Pharmaceutical Industries Ltd.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제